Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke
Dual Thrombolytic Therapy With Mutant Pro-urokinase (M-pro-urokinase, HisproUK) and Low Dose Alteplase for Ischemic Stroke
Randomized controlled phase II trial to test the safety and preliminary efficacy of a dual thrombolytic treatment consisting of a small intravenous (IV) bolus of alteplase followed by IV infusion of mutant pro-urokinase against usual treatment with IV alteplase in patients presenting with ischemic stroke.
Inclusion Criteria:
Exclusion Criteria:
Candidate for endovascular thrombectomy (i.e., a proximal intracranial large artery occlusion on CTA);
Contra-indication for treatment with IV alteplase according to national guidelines27:
Pre-stroke disability which interferes with the assessment of functional outcome at 90 days, i.e. mRS > 2;
Known pregnancy or if pregnancy cannot be excluded, i.e. did not have intercourse for > 6 months and no clinical signs of pregnancy, adequate use of any contraceptive method (e.g. intrauterine devices) or sterilization of the subject herself.
Contra-indication for an MRI scan, i.e.:
Current Participation in any medical or surgical therapeutic trial other than DUMAS.